ProKidney Corp (NASDAQ: PROK)’s stock price has gone decline by -18.00 in comparison to its previous close of 1.08, however, the company has experienced a -2.69% decrease in its stock price over the last five trading days. zacks.com reported 2025-03-21 that PROKIDNEY CP (PROK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Is It Worth Investing in ProKidney Corp (NASDAQ: PROK) Right Now?
Moreover, the 36-month beta value for PROK is 1.55. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for PROK is 91.19M and currently, short sellers hold a 14.57% of that float. On May 01, 2025, PROK’s average trading volume was 757.92K shares.
PROK’s Market Performance
PROK’s stock has seen a -2.69% decrease for the week, with a 1.07% rise in the past month and a -44.65% fall in the past quarter. The volatility ratio for the week is 16.22%, and the volatility levels for the past 30 days are at 23.47% for ProKidney Corp The simple moving average for the past 20 days is 13.43% for PROK’s stock, with a -47.76% simple moving average for the past 200 days.
Analysts’ Opinion of PROK
Guggenheim, on the other hand, stated in their research note that they expect to see PROK reach a price target of $6. The rating they have provided for PROK stocks is “Buy” according to the report published on September 10th, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to PROK, setting the target price at $3 in the report published on March 07th of the previous year.
PROK Trading at -8.86% from the 50-Day Moving Average
After a stumble in the market that brought PROK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.05% of loss for the given period.
Volatility was left at 23.47%, however, over the last 30 days, the volatility rate increased by 16.22%, as shares surge +6.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.12% lower at present.
During the last 5 trading sessions, PROK fell by -2.69%, which changed the moving average for the period of 200-days by -62.31% in comparison to the 20-day moving average, which settled at $0.7808. In addition, ProKidney Corp saw -47.60% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PROK starting from Control Empresarial de Capital, who purchase 387,393 shares at the price of $0.71 back on Apr 22 ’25. After this action, Control Empresarial de Capital now owns 73,842,723 shares of ProKidney Corp, valued at $276,366 using the latest closing price.
Control Empresarial de Capital, the Add’l Rep. Persons-see Ex.99-1 of ProKidney Corp, purchase 25,000 shares at $0.75 during a trade that took place back on Apr 17 ’25, which means that Control Empresarial de Capital is holding 73,455,330 shares at $18,690 based on the most recent closing price.
Stock Fundamentals for PROK
Current profitability levels for the company are sitting at:
- -2416.79 for the present operating margin
The net margin for ProKidney Corp stands at -1344.07. The total capital return value is set at -0.45.
Based on ProKidney Corp (PROK), the company’s capital structure generated -0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -51.13. The debt to equity ratio resting at -0.0. The interest coverage ratio of the stock is -20408.44.
Currently, EBITDA for the company is -158.49 million with net debt to EBITDA at 0.61. When we switch over and look at the enterprise to sales, we see a ratio of 2139.0. The receivables turnover for the company is 0.03for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.93.
Conclusion
To wrap up, the performance of ProKidney Corp (PROK) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
